PA-BENTLEY/AR2TECH
13.12.2021 22:03:12 CET | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced that its Seequent business unit has acquired Denver-based Advanced Resources and Risk Technology, LLC (AR2Tech), a developer of geostatistical software applications. The acquisition provides Seequent with state-of-the-art geostatistics algorithms, technology, and IP for complex geospatial problem solving, complementing its geological modeling solutions and workflows, to help solve earth, environmental, and resources challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005118/en/
AR2Tech represents a new generation of geostatistics and spatial data analysis solutions for mining, environmental sciences, and energy. Its state-of-the-art, high-performance algorithms and workflows for cloud and desktop enable users to create and optimize a diverse set of models, even with millions of cells, without performance bottlenecks. AR2Tech’s algorithm library can be applied to a wide range of geostatistical modeling and data science methods, supporting functions that are data-centric and rely on machine learning. Solutions can be used stand alone or integrated with other software, including Seequent’s Leapfrog 3D geological modeling solutions.
Mining companies use AR2Tech’s solutions for geostatistical modeling for conditional simulation and estimation models of complex orebodies, with algorithms customized for specific deposits. Environmental sciences professionals use customized workflows for data management, spatial evaluation, and risk assessment, designed for applications including stochastic simulation of the subsurface for water modeling, sampling evaluation and strategy, integration of remote sensing data in the geostatistical model, and characterization of pollutants.
Graham Grant, chief executive officer of Seequent, said, “We’re delighted to welcome to Seequent the elite and talented AR2Tech team in Denver and Brazil. AR2Tech’s technology stack and world-leading expertise in geostatistics, geomodeling, and spatial data integration strengthen Seequent’s capabilities in these areas. The acquisition will help accelerate our development of new geostatistics solutions and create seamless end-to-end workflows with Seequent’s advanced modeling solutions. We’re excited to make this investment for our mining, environmental, civil, and energy users to take geomodeling to the next level.”
AR2Tech founder Dr. Alexandre Boucher said, “We’re proud to be joining Seequent and sharing our cloud-first approach to solving geosciences challenges. With Seequent, we will realize our goal of bringing the next generation of geostatistical algorithms to the geomodeling community. We have developed and optimized algorithms for geomodeling for over a decade, including conditional simulations for risk and uncertainty studies. Combining forces with Seequent, we can create new practical and accessible solutions for geoscience professionals.”
For more information, please visit https://www.ar2tech.com/ .
##
About Seequent
Seequent, a Bentley company, is a world leader in the development of powerful geoscience analysis, modeling, and collaborative technologies for understanding geoscience and engineering design solutions. Our solutions enable people to analyze complex data, manage risk, and ultimately make better decisions about earth, environment, and energy challenges.
Seequent software is used on large-scale projects globally, including road and rail tunnel construction, groundwater detection and management, geothermal exploration, subsea infrastructure mapping, resource evaluation, and subterranean storage of spent nuclear fuel.
Seequent’s global footprint includes its Christchurch-based HQ and R&D centers in Christchurch and Canada with a network of offices across Asia/Pacific, Africa, South America, North America, and Europe, servicing organizations with leading subsurface solutions in over 100 countries. For more information, please visit www.seequent.com or follow Seequent on LinkedIn or Twitter .
About Bentley Systems
Bentley Systems (Nasdaq:BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation -based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, iTwin, Leapfrog, MicroStation, ProjectWise, Seequent, and the Seequent logo are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005118/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom